卵巢癌基因治疗研究进展
摘要
近年来对卵巢癌的基因治疗研究颇多,有的已进入临床试验阶段。对卵巢癌基因治疗的策略主要有分子化学治疗或前体药物治疗,针对突变的抑癌基因或癌基因治疗以及免疫增强治疗等。
出处
《国外医学（临床生物化学与检验学分册）》
2005年第7期447-448,451,共3页
Foreign Medical Sciences(section of Clinical Biochemistry and Laboratory Medicine
参考文献17
-
1Rancourt C, Robertson M-W 3rd, Wang M, et al. Endothelial cell vehicles for delivery of cytotoxic genes as a gene therapy approach for carcinoma of the ovary. Clin Cancer Res, 1998, 4(2): 265-70.
-
2McNeish IA, Green NK, Gilligan MG, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered E. coli nitroreductase and CB1954. Gene Ther, 1998, 5(8): 1061-1069.
-
3Spooner RA, Martin J, Friedlos F, et al. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Cancer Gene Ther, 2000, 7(10) : 1348-1356.
-
4Mandell RB, Mandell LZ, Link CJ Jr. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res, 1999, 59(3): 661-668.
-
5Tong XW, Kieback DG, Ramesh R, et al. Molecular aspects of ovarian cancer. Is gene therapy the solution? Hematol Oncol Clin North Am, 1999, 13(1): 109-133, viii.
-
6Kim J, Hwang ES, Kim JS, et al. Intraperitoneal gene therapy with adenoviral-mediated p53 tumor suppressor gene for ovarian cancer model in nude mouse. Cancer Gene Ther, 1999, 6(2): 172-178.
-
7Minaguchi T, Mori T, Kanamori Y, et al. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res, 1999, 59(24): 6063-6067.
-
8Wolf JK, Kim TE, Fightmaster D, et al. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol, 1999, 73(1): 27-34.
-
9Tait DL, Obermiller PS, Redlin-Frazier S, et al. A phase Ⅰ trial of retroviral BRCA1sv gene therapy in ovarian cancer.Clin Cancer Res, 1997, 3(11): 1959-1968.
-
10Tait DL, Obermiller PS, Hatmaker AR, et al. Ovarian cancer BRCA1 gene therapy: Phase Ⅰ and Ⅱ trial differences in immune response and vector stability. Clin Cancer Res, 1999, 5(7): 1708-1714.
-
1杨甲梅.大肝癌的肝移植治疗[J].腹部外科,2007,20(6):373-374. 被引量：3
-
2钟选芳,许岸高.大肠癌基因治疗的现状[J].实用医学杂志,2005,21(8):865-867. 被引量：1
-
3陈东,张桂英.结肠癌组织中Cyclin G与p53表达相关性研究[J].湖南师范大学学报（医学版）,2007,4(4):26-29.
-
4周华平,彭和平.胰腺癌基因治疗研究进展[J].中华普通外科学文献（电子版）,2009,3(3):12-14.
-
5杨友竹.p53基因用于癌基因治疗[J].日本医学介绍,1996,17(1):29-30.
-
6陶连元,何小东.胆管癌相关miRNA的研究进展[J].中华实验外科杂志,2008,25(10):1355-1356. 被引量：3
-
7牛东生,赵莉.大肠癌患者免疫状态的研究进展[J].国外医学（生理病理科学与临床分册）,2005,25(1):46-48. 被引量：6
-
8牛东生,赵莉.结肠癌患者免疫状态研究进展[J].国外医学（内科学分册）,2005,32(7):289-292.
-
9张晔.卵巢癌基因治疗研究现状及进展[J].国外医学（肿瘤学分册）,2003,30(5):392-395.
-
10关弘,温文,黄忠华,许美权,昝沁.胃癌患者外周血中T细胞亚群变化及临床意义[J].深圳中西医结合杂志,2009,19(3):138-141. 被引量：3
